Cancer Family
Female Reproductive System Adnexal Neoplasm
CI-CAN-00000180Explore in graph →
Non-malignant765 active trials5 approved drugs94 evidence items
- NCIt
- C212117
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000180Explore in graph →
Clinical trials
3,476 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00801320 | Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer | completed | N/A | 100 | Beth Israel Deaconess Medical CenterOTHER | 1 | Sep 10, 2020 | clinicaltrials |
| NCT03030287 | A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer | completed | Phase 1 | 44 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 3, 2020 |
| clinicaltrials |
| NCT01139957 | Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer | completed | — | 1,916 | Gynecologic Oncology GroupNETWORK | 1 | Sep 2, 2020 | clinicaltrials |
| NCT02297958 | Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian Carcinoma(IFFaLCCO) | completed | — | 28 | Rennes University HospitalOTHER | 1 | Aug 31, 2020 | clinicaltrials |
| NCT02121990 | Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | completed | Phase 1 | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 21, 2020 | clinicaltrials |
| NCT02658214 | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors | completed | Phase 1 | 32 | AstraZenecaINDUSTRY | 2 | Aug 20, 2020 | clinicaltrials |
| NCT03158935 | The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial(ACTIVATE) | completed | Phase 1 | 8 | University Health Network, TorontoOTHER | 1 | Aug 14, 2020 | clinicaltrials |
| NCT02092363 | Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer | completed | Phase 1 | 37 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 12, 2020 | clinicaltrials |
| NCT04507191 | PDL1 in Ovarian High Grade Serous Carcinoma | completed | — | 54 | Port Said University hospitalOTHER | 1 | Aug 11, 2020 | clinicaltrials |
| NCT03656809 | Feasibility of Multi-gene Panel Testing at the Time of Diagnosis for Patients With Ovarian Cancer | completed | — | 125 | NYU Langone HealthOTHER | 1 | Aug 10, 2020 | clinicaltrials |
| NCT03430518 | Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer | completed | Phase 1 | 9 | Amy TierstenOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT03082976 | Prevalence of BRCA1 and BRCA2 Mutations in Ovarian Cancer Patients in the Gulf Region(PREDICT) | completed | — | 108 | AstraZenecaINDUSTRY | 1 | Jul 16, 2020 | clinicaltrials |
| NCT02714621 | MR-HIFU for Recurrent Gynaecological Cancer(HIFU-Gynae) | completed | N/A | 31 | Institute of Cancer Research, United KingdomOTHER | 1 | Jul 15, 2020 | clinicaltrials |
| NCT01611558 | Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer | completed | Phase 2 | 40 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 13, 2020 | clinicaltrials |
| NCT02984423 | FLABRA: Frontline Approach for BRCA Testing in OC Treatment naïve Population. A LATIN AMERICA Epidemiologic Study(FLABRA) | completed | — | 471 | AstraZenecaINDUSTRY | 6 | Jul 10, 2020 | clinicaltrials |
| NCT04461457 | Targeted Radiation Therapy for Ovarian Cancer: Intraperitoneal Treatment With 211-astatine-MX35 F(ab')2 | completed | Early Phase 1 | 12 | Vastra Gotaland RegionOTHER_GOV | 1 | Jul 8, 2020 | clinicaltrials |
| NCT04135521 | Dose-dense Chemotherapy Versus Intraperitoneal Chemotherapy as First-line Chemotherapy in Advanced Ovarian Cancer | completed | — | 50 | Far Eastern Memorial HospitalOTHER | 1 | Jun 29, 2020 | clinicaltrials |
| NCT02144311 | Benchmarking Intra-tumor Heterogeneity In Ovarian Cancer: Linking In-vivo Imaging Phenotypes With Histology And Genomics | completed | N/A | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 18, 2020 | clinicaltrials |
| NCT03543462 | Diaphragmatic Resection And Gynecological Ovarian Neoplasm(DRAGON) | completed | Phase 4 | 88 | Catholic University of the Sacred HeartOTHER | 1 | May 22, 2020 | clinicaltrials |
| NCT02090582 | H.O.P.E: Helping Ovarian Cancer Patients Cope | completed | N/A | 47 | Duke UniversityOTHER | 1 | May 13, 2020 | clinicaltrials |
| NCT03175991 | Gynacological Imaging Reporting and Data System in Ovarian Masses by Ultrasonography | completed | — | 123 | Assiut UniversityOTHER | 1 | May 12, 2020 | clinicaltrials |
| NCT00849199 | Cancer Screening and Prevention Program for High Risk Women | completed | — | 1,452 | NYU Langone HealthOTHER | 1 | May 6, 2020 | clinicaltrials |
| NCT01580696 | Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer | completed | Phase 1 / Phase 2 | 51 | COL George Peoples, MD, FACSFED | 1 | May 4, 2020 | clinicaltrials |
| NCT01370122 | Pelvic Floor Disorders in Survivors of Gynecologic Malignancies | completed | — | 225 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 29, 2020 | clinicaltrials |
| NCT01711970 | A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer | completed | Phase 1 / Phase 2 | 38 | Vascular Biogenics Ltd. operating as VBL TherapeuticsINDUSTRY | 1 | Apr 24, 2020 | clinicaltrials |
| NCT00341458 | Breast Cancer in Poland: An Expanded Study to Assess Occupational and Environmental Factors and Interactions With Genetics | completed | — | 6,086 | National Cancer Institute (NCI)NIH | 1 | Apr 20, 2020 | clinicaltrials |
| NCT02529150 | WISER After Ovarian Cancer - Exercise Pilot Study | completed | N/A | 10 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 16, 2020 | clinicaltrials |
| NCT01831089 | Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors | completed | Phase 1 | 69 | PharmaMarINDUSTRY | 3 | Apr 10, 2020 | clinicaltrials |
| NCT00030446 | Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 50 | NCIC Clinical Trials GroupNETWORK | 1 | Apr 8, 2020 | clinicaltrials |
| NCT00003892 | ISIS 5132 in Treating Patients With Metastatic or Recurrent Ovarian Cancer | completed | Phase 2 | 22 | NCIC Clinical Trials GroupNETWORK | 3 | Apr 6, 2020 | clinicaltrials |
| NCT00006036 | Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors | completed | Phase 1 | 14 | NCIC Clinical Trials GroupNETWORK | 1 | Apr 6, 2020 | clinicaltrials |
| NCT00010179 | Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer | completed | Phase 2 | 81 | NCIC Clinical Trials GroupNETWORK | 2 | Apr 6, 2020 | clinicaltrials |
| NCT02421588 | Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients(CORAIL) | completed | Phase 3 | 442 | PharmaMarINDUSTRY | 1 | Apr 3, 2020 | clinicaltrials |
| NCT00028743 | Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | completed | Phase 3 | 819 | NCIC Clinical Trials GroupNETWORK | 1 | Apr 2, 2020 | clinicaltrials |
| NCT03069872 | A Trial of Fast Access to Transvaginal Ultrasound Through General Practice for Earlier Diagnosis of Ovarian Cancer | completed | N/A | 490 | University of AarhusOTHER | 1 | Apr 2, 2020 | clinicaltrials |
| NCT04284631 | Prognostic Value of Her2neu and EGFR in Primary Ovarian High Grade Serous Carcinoma. | completed | — | 54 | Port Said University hospitalOTHER | 0 | Apr 1, 2020 | clinicaltrials |
| NCT01536054 | Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Phase 1 | 7 | Roswell Park Cancer InstituteOTHER | 1 | Mar 27, 2020 | clinicaltrials |
| NCT02962596 | EURAD MRI Classification of US Indeterminate Adnexa Lesions | completed | — | 1,340 | University of Wisconsin, MadisonOTHER | 1 | Mar 26, 2020 | clinicaltrials |
| NCT00305695 | Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries | completed | Phase 2 | 160 | Gynecologic Oncology GroupNETWORK | 1 | Mar 24, 2020 | clinicaltrials |
| NCT00390182 | Low Dose Upper Abdominal Radiation Therapy (LD-UART) + Gemcitabine in Patients With Advanced, Unresectable Pancreatic Cancer (PC)(GCC0319) | completed | Phase 1 / Phase 2 | 38 | University of Maryland, BaltimoreOTHER | 2 | Mar 18, 2020 | clinicaltrials |
| NCT02019524 | Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients(J65) | completed | Phase 1 | 39 | COL George Peoples, MD, FACSFED | 1 | Mar 18, 2020 | clinicaltrials |
| NCT00001938 | A Pilot Study of a Protein Profile Test in Ovarian Cancer Patients in Remission to See if Protein Changes Can Predict Relapse (be Predictive of Cancer Relapse) | completed | — | 26 | National Cancer Institute (NCI)NIH | 1 | Mar 12, 2020 | clinicaltrials |
| NCT00477282 | Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer | completed | Phase 3 | 509 | BioNumerik Pharmaceuticals, Inc.INDUSTRY | 5 | Mar 12, 2020 | clinicaltrials |
| NCT00692900 | Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer | completed | Phase 1 | 25 | University of PittsburghOTHER | 1 | Mar 12, 2020 | clinicaltrials |
| NCT01716715 | Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Phase 2 | 111 | National Cancer Institute (NCI)NIH | 1 | Mar 10, 2020 | clinicaltrials |
| NCT02315430 | Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 1 | Mar 10, 2020 | clinicaltrials |
| NCT00006227 | Paclitaxel in Treating Patients With Ovarian Stromal Cancer | completed | Phase 2 | 31 | Gynecologic Oncology GroupNETWORK | 2 | Mar 5, 2020 | clinicaltrials |
| NCT00712218 | Lymphadenectomy In Ovarian Neoplasms(LION) | completed | N/A | 640 | Philipps University MarburgOTHER | 6 | Mar 4, 2020 | clinicaltrials |
| NCT02287519 | Sexual Therapy and Rehabilitation After Treatment for Ovarian Cancer (START-OC): A Pilot Intervention(START-OC) | completed | N/A | 53 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 28, 2020 | clinicaltrials |
| NCT03242993 | [18F]-AZAFOL AS POSITRON EMISSION TOMOGRAPHY (PET) TRACER in FR Positive Cancer Imaging | completed | Phase 1 | 15 | University of Lausanne HospitalsOTHER | 1 | Feb 28, 2020 | clinicaltrials |
Data updated 24 days agoSource updated Sep 10, 2020source: clinicaltrials